SANUWAVE Announces Exhibition at Fall SAWC 2018 Including a Poster and Three Presentations - Visit us at Booth #441


SUWANEE, GA , Oct. 17, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company will exhibit at SAWC (Symposium on Advanced Wound Care) in Las Vegas, NV on November 2 - 4, 2018. This is SANUWAVE’s next opportunity to showcase their wound care device, the dermaPACE® System, which received FDA clearance in December, allowing the company to market the device in the United States. 

“The wound care community continues to provide excitement and encouragement for our commercialization journey,” stated Kevin A. Richardson, CEO and Chairman of the Board.  Mr. Richardson continued, “We are excited to return to SAWC this fall and share in the enthusiasm around three events involving our researchers:

  •  A poster and presentation from Suzanne Kapp PhD, Department of Nursing, The University of Melbourne (Australia) titled: Treating Leg Ulcers with Extracorporeal Shockwave Technology (ESWT), to be presented Saturday evening, November 3; 
  •  Accelerating Chronic Wound Healing:  Integrating the Use of Non-Invasive Diagnostic Imaging and Extracorporeal Shock-Wave Therapy; presented by Oscar Alvarez, PhD, CCT, FAPWCA and Stephen Bergquist, MD, CWSP (A joint presentation with SANUWAVE and HyperMed Imaging Inc.) presented on Saturday, November 3 at 11:20 AM;
  •  What’s New in Wound Care Technology, featuring a discussion on ESWT by Oscar Alvarez, PhD, CCT, FAPWCA and Mark S. Granick, MD, to be conducted at 2:00 PM on Sunday, November 4.

These three events all discuss the healing properties of the dermaPACE® System or Extracorporeal Shock-Wave Therapy. This conference continues to highlight SANUWAVE’s innovative presence in the wound care space through the dermaPACE® System.”  

This Extracorporeal Shockwave Technology (ESWT), based upon electrohydraulic principles, has been proven in two US based clinical trials enrolling 336 subjects to be safe and effective in the treatment of Diabetic Foot Ulcers (DFU).  Within a few weeks of initial treatment, wounds treated with dermaPACE® reduce in area at superior rates compared to control subjects.  The dermaPACE® System exhibits superiority in wound area reduction within 12 weeks of initial treatment and exhibits superiority in wound closure within 20 weeks of initial treatment.  The use of the dermaPACE® System allows the clinician to more easily, and more cost-effectively, manage wounds.  Most importantly, the patient’s quality of life improves significantly. 

If you are interested in scheduling a meeting with the SANUWAVE team, please contact Pete Stegagno, Chief Operating Officer via e-mail at Pete.Stegagno@sanuwave.com or Lorraine Bittinger BSN, RN, Clinical Affairs Manager at Lorraine.Bittinger@sanuwave.com; otherwise, please stop by Booth Number 441.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers.  The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit www.SANUWAVE.com.



            

Contact Data